--- canonical_name: Coluracetam alternate_names: BCI-540, MKC-231, BCI540, MKC231 canonical_topic: Coluracetam for Health & Longevity short_topic_lc: coluracetam creation_date: 2026-0621-0302 creator_ai_fullname: Opus 4.8 ep_keywords: Racetams, Nootropics --- # Coluracetam for Health & Longevity
Evidence Review created on 06/21/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** BCI-540, MKC-231, BCI540, MKC231 ## Motivation Coluracetam (also known as BCI-540 and MKC-231) is a synthetic compound from the racetam family — the same chemical family as piracetam, the first widely used "smart drug." It was originally created in Japan as a candidate medicine for Alzheimer's-type memory loss. What sets it apart from other racetams is its proposed main action: it appears to boost the brain's ability to pull in choline, the raw material the body uses to make acetylcholine, a signaling chemical central to memory and attention. The compound has an unusual history. After its developer halted work on it for memory loss, a second company tested it in people with hard-to-treat depression and anxiety, then also set it aside. Today it is sold mainly online as a research chemical rather than an approved medicine or dietary supplement, and most of what is claimed about it comes from animal studies and self-reports rather than completed human trials. This review examines what the available evidence shows about coluracetam — its proposed mechanism, the limited human and animal data, its safety record, and the practical and regulatory questions that surround a compound used outside any approval framework. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists high-level overviews and primary commentary that introduce coluracetam, its proposed effects, and its clinical history. - [Coluracetam: Review of Benefits, Effects, Dosage, and More](https://www.braintropic.com/nootropics/coluracetam/) - Braintropic A structured plain-language overview covering coluracetam's racetam classification, choline-uptake mechanism, reported effects, dosing ranges, and stacking practices, useful as an orientation to how the compound is discussed in the nootropic community. - [Coluracetam: The $16,000 Lucidifying Smart Drug](https://www.limitlessmindset.com/nootropic-ingredients/301-coluracetam) - Jonathan Roseland Long-form expert commentary that traces the compound's Japanese pharmaceutical origin and catalogs user-reported experiences, providing context on the gap between mechanistic promise and the thin human evidence base. - [Coluracetam: Nootropic Benefits, Dosage, & Side Effects](https://www.wholisticresearch.com/coluracetam/) - Jacob Kovacs A benefit-and-risk summary that consolidates the animal-study findings and self-reported side-effect profile, helpful for understanding the limits of the current data and the role of co-supplementation with choline. - [The Effects of Cognitive Enhancement Drug (Coluracetam) on Visual Perception, Abstract Reasoning, Pattern Recognition, Spatial Orientation, and Analytical Thinking: A Case Study](https://clinmedjournals.org/articles/ijcb/international-journal-of-cognition-and-behaviour-ijcb-6-016.php?jid=ijcb) - Villarino & Villarino, 2023 A single-subject case report examining cognitive-test changes after coluracetam use; while it cannot establish efficacy, it is one of the few published human-facing accounts and illustrates both the type of effect claimed and the weakness of uncontrolled observation. - [BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety](https://www.biospace.com/article/releases/braincells-inc-initiates-phase-2-clinical-trial-with-bci-540-for-depression-with-anxiety-/) - BioSpace The 2008 press release announcing the only registered human trial of coluracetam, valuable for documenting the compound's transition from a memory-loss candidate to a depression-and-anxiety candidate and the rationale behind that pivot. ## Grokipedia [Coluracetam](https://grokipedia.com/page/Coluracetam) The Grokipedia entry compiles coluracetam's chemistry, pharmacology, development history, and reported effects into a single reference, providing a broad if AI-generated synthesis of the scattered literature. ## Examine [Coluracetam benefits, dosage, and side effects](https://examine.com/supplements/coluracetam/) Examine's page summarizes the evidence with its characteristic conservatism, concluding that coluracetam preserves choline uptake in impaired neurons but that there is currently no evidence for inherent cognitive-enhancing effects in healthy people. ## ConsumerLab No ConsumerLab article exists for coluracetam. ConsumerLab focuses on testing commercially marketed dietary supplements and consumer health products; coluracetam is sold as an unregulated research chemical rather than a labeled supplement, so it falls outside ConsumerLab's testing scope. ## Systematic Reviews No systematic reviews or meta-analyses for Coluracetam were found on PubMed as of 2026-06-21. ## Mechanism of Action Coluracetam's primary proposed mechanism is enhancement of **high-affinity choline uptake (HACU)** — the energy-dependent transport of choline into nerve terminals. HACU is the rate-limiting step in the manufacture of acetylcholine (ACh), the neurotransmitter most associated with memory, learning, and attention. By accelerating choline entry, coluracetam is thought to increase the supply of raw material for ACh synthesis. The mechanistic detail comes mainly from work on the high-affinity choline transporter 1 (CHT1, the protein that carries choline across the nerve-cell membrane). Laboratory studies indicate coluracetam binds CHT1 and increases the number of functional transporters at the synaptic membrane, raising both the maximum transport rate and the density of transporter binding sites, rather than simply activating existing transporters. A distinctive feature reported in animal work is that the effect appears selective for impaired neurons: coluracetam increased choline uptake in tissue from animals with chemically damaged cholinergic systems but had little effect in healthy tissue. This "restorative-not-additive" pattern is the basis for the view that it may do little in an undamaged brain. Two further mechanistic strands appear in the preclinical literature. Coluracetam has shown neuroprotective effects against glutamate-induced toxicity in cultured neurons, attributed to suppression of calcium-triggered nitric oxide formation. Separately, an antidepressant-relevant hypothesis emerged from later human development, where the compound was tested on the premise that boosting cholinergic and neurogenic activity might help mood disorders. A competing interpretation, however, holds that because the choline-uptake effect is largely confined to compromised neurons, the compound's relevance to healthy cognition is mechanistically uncertain — a tension the evidence has not resolved. As a pharmacological compound, coluracetam's key properties are only partly characterized. It is orally active and lipophilic, crossing the blood-brain barrier. Its elimination half-life in humans is reported to be short, on the order of 2–3 hours. A notable preclinical finding is that procognitive effects in animals persisted well beyond the point at which the parent compound was detectable in brain tissue, suggesting the effect may involve a lasting change in transporter regulation rather than continuous drug presence. Detailed human data on tissue distribution and the specific metabolizing enzymes (e.g., particular cytochrome P450 isoforms — the liver's main drug-processing enzymes) have not been published. ## Historical Context & Evolution Coluracetam was synthesized in the 1990s by the Japanese firm Mitsubishi Tanabe Pharma (then Mitsubishi Chemical), with the compound code MKC-231. Its original intended use was as a treatment for the cognitive decline of Alzheimer's disease, pursued through the then-dominant "cholinergic hypothesis" — the idea that the memory loss of dementia stems largely from a loss of acetylcholine signaling, and that restoring it could help. The early research findings were substantive rather than merely promising. In rodent models where the cholinergic system was deliberately damaged with the toxin AF64A (ethylcholine aziridinium), coluracetam restored high-affinity choline uptake, reversed acetylcholine depletion in the hippocampus, and improved performance on water-maze and working-memory tasks — and it did so without the tremor, salivation, and low body temperature seen with the comparison drug tacrine. Repeated dosing produced cognitive improvement that outlasted the drug's presence in the brain. Despite these results, Mitsubishi did not bring the compound to market for dementia, and development under the original indication lapsed. The compound was later licensed to the U.S. biopharmaceutical company BrainCells Inc., which renamed it BCI-540 and repositioned it. Reasoning that compounds promoting new neuron growth and cholinergic activity might help mood disorders, BrainCells launched a Phase 2 trial in 2008 for major depressive disorder with co-occurring anxiety in patients who had failed prior antidepressants. The headline result was negative — no overall benefit over placebo — but a post-hoc analysis suggested a possible signal in a subgroup with generalized anxiety disorder. BrainCells did not advance the compound further. The current standing is therefore unsettled: the preclinical case for choline-uptake enhancement remains scientifically intact, while no human indication has been established, and the compound migrated into the gray-market nootropic world rather than the clinic. A conflict of interest should be noted here: nearly all of the favorable efficacy evidence was generated by parties with a direct financial stake in the compound — the foundational animal studies by the developer Mitsubishi (the authors were Mitsubishi-affiliated) and the sole human trial by its licensee and sponsor, BrainCells Inc. This does not invalidate the findings, but it means the positive signal comes largely from interested sources rather than independent replication. ## Expected Benefits A dedicated search of preclinical literature, the single registered human trial, expert nootropic sources, and Examine's evidence summary was performed to compile the benefit profile. The defining feature of coluracetam's evidence is that nearly all positive findings come from animal models of cholinergic damage, with essentially no controlled evidence of benefit in healthy humans. ### Low 🟩 #### Restoration of Memory and Learning in Cholinergic Impairment In rodents whose cholinergic systems were chemically damaged, coluracetam consistently restored high-affinity choline uptake, reversed hippocampal acetylcholine depletion, and improved performance on water-maze and working-memory tasks. The proposed mechanism is increased availability of the transporter that supplies choline for acetylcholine synthesis. The evidence is reproducible across multiple independent rodent studies but is confined to damaged-system models and has not been tested in a controlled human trial, so the relevance to human memory remains unestablished. **Magnitude:** In AF64A-damaged rats, oral doses of 1–10 mg/kg significantly improved maze-learning deficits; effects on choline uptake increased the maximum transport rate roughly 1.6-fold versus impaired controls. ### Speculative 🟨 #### General Cognitive Enhancement in Healthy Individuals Marketed and self-reported as a memory, focus, and learning aid, coluracetam is widely used by healthy people seeking cognitive enhancement. However, the mechanistic finding that its choline-uptake effect is largely confined to impaired neurons argues against a clear benefit in an undamaged brain, and Examine's review concludes there is no evidence for inherent cognitive-enhancing effects. The basis for this claimed benefit is anecdotal user reports and a single uncontrolled case study, not controlled data. #### Mood and Anxiety Improvement The only registered human trial tested coluracetam for treatment-resistant depression with anxiety and was negative overall; a post-hoc subgroup signal in generalized anxiety disorder generated interest but was never confirmed in a follow-up study. The proposed basis is cholinergic and possibly neurogenic activity. Because the primary result failed and the subgroup finding is hypothesis-generating only, any mood or anxiety benefit is speculative. #### Visual and Perceptual Enhancement Users frequently report enhanced color vibrancy and visual clarity, and a single-subject case study reported gains on visual-perception and pattern-recognition tasks. There is a loose mechanistic rationale via cholinergic signaling in the visual system, but no controlled human data exist; the basis is anecdotal and a single uncontrolled report. #### Neuroprotection In cultured neurons, coluracetam reduced glutamate- and calcium-driven toxicity, suggesting a possible protective role relevant to neurodegeneration. This is purely a cell-culture finding with no animal or human outcome data, so any neuroprotective or longevity-relevant benefit is speculative. ## Benefit-Modifying Factors The following factors are reasoned from the compound's mechanism and the available preclinical data; direct human evidence on effect modification is absent. - **Baseline cholinergic status:** Because the choline-uptake effect appears largely restricted to impaired neurons in animal models, individuals with intact, healthy cholinergic function may experience little benefit, whereas those with cholinergic deficits (the population originally targeted) may be more responsive. - **Baseline choline intake:** Adequate dietary or supplemental choline provides the substrate the transporter delivers; low choline status could blunt any acetylcholine-related benefit and is also linked to side effects in users. - **Pre-existing health conditions:** The strongest preclinical signals come from models of cholinergic damage and dementia-type impairment, suggesting any benefit may be larger where cholinergic dysfunction is present than in healthy individuals. - **Age-related considerations:** Cholinergic signaling tends to decline with age; older members of the target audience might in theory derive more from a choline-uptake enhancer, though this is untested in humans and must be weighed against the absence of long-term safety data. - **Sex-based differences:** No data on sex-based differences in benefit have been published for coluracetam; this remains uncharacterized. ## Potential Risks & Side Effects A dedicated search of the single registered human trial's safety reporting, expert nootropic sources, user-experience compilations, and preclinical toxicity data was performed. The central caveat is that no formal human safety database, prescribing information, or long-term toxicology exists, because the compound was never approved; the risk picture rests on a small short-term trial and self-reports. ### Low 🟥 #### Headache Headache is among the most commonly reported user side effects and is often attributed to the increased demand for choline outpacing supply when acetylcholine turnover rises. It is generally described as mild and responsive to reducing the dose or adding a choline source. The evidence is from self-reports rather than controlled data. **Magnitude:** Not quantified in available studies. #### Nausea and Gastrointestinal Upset Users report intermittent nausea, which is frequently lessened by lowering the dose. The proposed mechanism is non-specific gastrointestinal irritation or cholinergic stimulation. Evidence is anecdotal, with no systematic frequency data available. **Magnitude:** Not quantified in available studies. #### Fatigue and Daytime Sleepiness Daytime sleepiness and fatigue are reported by some users and tend to improve with dose reduction. The mechanism is unclear; it may relate to cholinergic effects on arousal. The evidence base is self-report only. **Magnitude:** Not quantified in available studies. #### Irritability Irritability appears in user reports and, like the other effects, is described as dose-related. No controlled data characterize its frequency or severity. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Unknown Long-Term and Chronic-Use Risks Because coluracetam has never completed a long-term human safety program, the consequences of chronic daily use are genuinely unknown. The longest controlled human exposure is the roughly six-week Phase 2 trial. This is the single most important risk: the absence of toxicology, carcinogenicity, and reproductive-safety data means potential harms cannot be ruled out, only described as uncharacterized. #### Tolerance Self-reports suggest tolerance can develop with continued use, requiring larger doses for the same effect. The mechanistic basis is unclear and could involve transporter or receptor adaptation. There are no controlled data confirming tolerance or quantifying its time course. #### Product Quality and Contamination Hazards As an unregulated research chemical, coluracetam carries risks unrelated to its pharmacology: mislabeling, incorrect dosing, and contamination from unverified suppliers. This is a hazard of the supply chain rather than the molecule, and its likelihood depends entirely on sourcing. ## Risk-Modifying Factors Direct human data on what modifies coluracetam's risks are unavailable; the following are reasoned from its mechanism and reported use patterns. - **Choline co-supplementation:** Inadequate choline appears to worsen the most common side effect (headache); ensuring sufficient choline intake may modify the likelihood of cholinergic-deficit symptoms. - **Dose level:** Reported side effects (nausea, fatigue, irritability, sleepiness) are consistently described as dose-dependent and improving with reduction, making dose the most actionable modifier. - **Source quality:** Risk of contamination or mislabeling is strongly modified by supplier reliability and third-party testing, given the unregulated market. - **Pre-existing health conditions:** People with cholinergic-sensitive conditions, psychiatric conditions, or those on cholinergic medications may face altered risk, though no condition-specific human data exist. - **Age and sex:** No published data characterize age- or sex-based differences in coluracetam's side-effect profile; these remain uncharacterized. ## Key Interactions & Contraindications Coluracetam has not been formally studied for drug interactions; the following are reasoned from its cholinergic mechanism and should be treated as theoretical. - **Cholinergic drugs (acetylcholinesterase inhibitors such as donepezil, rivastigmine, galantamine):** Caution — additive cholinergic effect. Combining a choline-uptake enhancer with drugs that slow acetylcholine breakdown could in theory cause excessive cholinergic activity (nausea, sweating, slowed heart rate). Monitor for cholinergic symptoms; separation or avoidance is prudent. - **Anticholinergic medications (over-the-counter antihistamines such as diphenhydramine, and antimuscarinics):** Caution — opposing actions. These may blunt coluracetam's intended effect, and the clinical consequence is reduced efficacy rather than harm. - **Choline-donor supplements (alpha-GPC, CDP-choline/citicoline):** Caution and commonly combined — additive cholinergic effect. These are frequently stacked with coluracetam to supply substrate; the trade-off is a higher chance of cholinergic side effects such as headache if combined at high doses. - **Other racetams (piracetam, aniracetam, oxiracetam):** Caution — overlapping cholinergic demand. Stacking may increase choline demand and the likelihood of headache; no interaction safety data exist. - **Psychiatric medications (antidepressants, anxiolytics):** Caution — uncharacterized. Coluracetam was itself trialed in depression with anxiety; combining it with psychiatric drugs has no safety data and a theoretical potential for additive or unpredictable central effects. - **Populations who should avoid it:** Pregnant or breastfeeding individuals (no reproductive-safety data); children and adolescents (no data); individuals with significant cardiac conduction abnormalities (e.g., symptomatic bradycardia or high-grade heart block) given the theoretical cholinergic effect on heart rate; and anyone unable to verify product identity and purity. ## Risk Mitigation Strategies - **Start low and titrate slowly:** Begin at the low end of reported ranges (e.g., 5 mg) and increase gradually only if tolerated, to reduce dose-dependent nausea, fatigue, irritability, and headache. - **Co-administer adequate choline:** Pair use with a choline source (e.g., alpha-GPC or citicoline at typical nootropic doses) to mitigate the headache attributed to choline depletion during increased acetylcholine turnover. - **Use third-party-tested product:** Obtain material with a certificate of analysis confirming identity and purity to mitigate the contamination and mislabeling risks inherent to an unregulated research chemical. - **Limit duration and reassess:** Given the absence of long-term safety data, keep trials short and reassess regularly rather than committing to indefinite daily use, to limit exposure to uncharacterized chronic-use risk. - **Avoid stacking cholinergic agents at high doses:** Do not combine with acetylcholinesterase inhibitors or high-dose choline donors simultaneously, to prevent additive cholinergic side effects. - **Screen for cardiac and psychiatric vulnerability:** Avoid use with significant cardiac conduction problems or unstable psychiatric conditions, given the theoretical cholinergic and central effects and the lack of interaction data. ## Therapeutic Protocol No standard clinical protocol exists, because coluracetam is not an approved medicine. The following reflects how the compound is used in the nootropic community and the dosing used in its single human trial, not validated clinical guidance. - **Common community dosing:** Reported daily ranges run from roughly 5 mg to 35 mg, with some sources citing up to 80 mg per day, typically divided into two or three doses. - **Clinical-trial dosing reference:** In the BrainCells Phase 2 trial, the signal of interest appeared in the three-times-daily dosing arm, consistent with the compound's short half-life and the community practice of splitting doses. - **Dose splitting:** Because the elimination half-life is short (about 2–3 hours), splitting into multiple daily doses is the common approach to maintain effect across the day. - **Half-life consideration:** The short half-life means a single morning dose is unlikely to last the full day; however, a distinctive preclinical finding that effects outlasted drug presence complicates simple half-life-based scheduling. - **Best time of day:** Users commonly take it earlier in the day and avoid late dosing because of reported daytime sleepiness in some and the desire not to disrupt sleep; there is no controlled evidence on optimal timing. - **Choline pairing:** It is commonly co-administered with a choline source to supply substrate and reduce headache. - **Genetic considerations:** No pharmacogenetic data (e.g., variants in choline-transporter or cytochrome P450 genes) have been published to guide dose individualization. - **Sex-based considerations:** No sex-specific dosing data exist. - **Age-related considerations:** No age-stratified dosing data exist; older adults must weigh the theoretical greater cholinergic responsiveness against the absence of safety data. - **Baseline biomarkers and conditions:** No biomarker-guided dosing is established; the mechanism suggests responders may be those with cholinergic deficits rather than healthy individuals. ## Discontinuation & Cycling - **Intended duration:** Coluracetam is not established as either a lifelong or fixed short-term therapy; given the lack of long-term safety data, indefinite continuous use is not supported by evidence. - **Withdrawal effects:** No formal withdrawal syndrome has been documented; the compound's short half-life and the lack of controlled discontinuation studies mean withdrawal effects are essentially uncharacterized. - **Tapering:** No tapering protocol has been studied; because no dependence syndrome is documented, abrupt discontinuation is the de facto community practice, though this is not evidence-based. - **Cycling:** Some users cycle the compound to counter reported tolerance, taking periodic breaks; there is no controlled evidence that cycling preserves efficacy, and the reported tolerance time course is anecdotal. ## Sourcing and Quality - **Regulatory category:** Coluracetam is sold as a research chemical, not as an approved drug or a labeled dietary supplement, which means no regulatory body verifies its identity, purity, or dosing. - **Third-party testing:** The single most important quality safeguard is a current certificate of analysis from an independent laboratory confirming compound identity and purity; without it, contents cannot be assumed accurate. - **Formulation:** It is sold as bulk powder and in capsules; the very small effective doses make accurate measurement of bulk powder difficult, favoring verified pre-measured forms for dose precision. - **Supplier reliability:** Because the market is unregulated, reputable vendors are those that publish batch-specific testing and have an established track record; products without testing documentation carry elevated mislabeling and contamination risk. - **Storage:** As with most racetams, it should be kept cool, dry, and away from light to preserve stability, though formal stability data are limited. ## Practical Considerations - **Time to effect:** Users report acute effects within roughly 15–60 minutes of an oral dose, while the substantive preclinical cognitive effects emerged only after repeated dosing over days, so a single dose may not reflect the compound's full reported profile. - **Common pitfalls:** Frequent mistakes include dosing without adequate choline (worsening headache), measuring tiny doses inaccurately from bulk powder, sourcing from untested vendors, and extrapolating animal findings in damaged brains to healthy human cognition. - **Regulatory status:** Coluracetam has no marketing approval anywhere; in the United States it is neither an approved drug nor a permitted dietary-supplement ingredient and is sold for research use only, placing personal use in a legal and quality-control gray zone. - **Cost and accessibility:** It is generally inexpensive and available online from research-chemical vendors, but accessibility is offset by the absence of pharmacy-grade quality assurance. ## Interaction with Foundational Habits - **Sleep:** Indirect, potentially disruptive. Some users report daytime sleepiness while others report stimulation; late-day dosing is commonly avoided to prevent sleep disruption. No controlled data exist on sleep architecture, so timing earlier in the day is the practical precaution. - **Nutrition:** Direct and potentiating. Adequate dietary choline (eggs, liver, soy) or supplemental choline supplies the substrate the compound's transporter delivers; low choline status may both blunt any benefit and worsen headache, making sufficient choline intake the key nutritional pairing. - **Exercise:** None established. There is no evidence that coluracetam blunts or enhances exercise adaptations, and no mechanism specifically links it to hypertrophy or endurance; timing around workouts is not supported by data. - **Stress management:** Indirect and uncertain. The compound was trialed in anxiety-related depression with a negative primary result; any effect on the stress response or cortisol is unproven, so it should not be relied upon as a stress-management tool. ## Monitoring Protocol & Defining Success No formal monitoring protocol has been established for coluracetam, because it has no approved clinical use and no recognized biomarker of effect. Given the unregulated status and absence of long-term safety data, general safety monitoring before and during any trial is reasonable, but no laboratory test specifically tracks the compound's action. The table below lists general-purpose markers a cautious user might check rather than coluracetam-specific tests. Baseline testing before starting would prudently establish general organ-function status so that any change during use can be detected. Ongoing monitoring has no validated cadence for this compound; checking general markers at baseline, then at roughly 8–12 weeks, and periodically (every 6–12 months) during continued use is a conservative default rather than evidence-based guidance. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | ALT / AST | ALT ~10–26 U/L; AST ~10–26 U/L | Screens for liver stress from an unstudied compound | ALT/AST are liver enzymes; conventional upper limits (~40 U/L) are higher than functional targets; fasting not required | | Resting heart rate | ~55–70 bpm | Cholinergic activity can lower heart rate; flags excessive effect | Measure at rest, ideally morning; relevant given theoretical cholinergic action | | CBC | Hemoglobin ~14–15 g/dL (men), ~13.5–14.5 g/dL (women); WBC ~3.5–6.0 ×10⁹/L | General safety screen for an unregulated product | CBC (complete blood count) is a broad blood-cell panel; WBC (white blood cell count) reflects immune-cell numbers; functional targets sit mid-range and tighter than conventional limits (e.g., WBC ~4.0–11.0 ×10⁹/L); a baseline catch-all given possible contamination risk | | CMP | Fasting glucose ~75–85 mg/dL; kidney filtration rate >90 mL/min/1.73m²; sodium/potassium mid-range | General organ-function and electrolyte safety screen | CMP (comprehensive metabolic panel) is a broad metabolic and kidney/liver panel; functional glucose target is tighter than the conventional ~65–99 mg/dL; fasting preferred | Qualitative markers are, in practice, the main way users judge effect, since no objective test tracks the compound: - Subjective memory, focus, and learning performance - Self-reported visual clarity or color vibrancy (commonly cited) - Mood and anxiety levels - Presence of side effects (headache, nausea, fatigue, irritability) as a signal to reduce dose ## Emerging Research - **Only registered human trial (completed, not advanced):** The single registered human study, [NCT00621270](https://clinicaltrials.gov/study/NCT00621270), a Phase 2 trial of BCI-540 versus placebo in major depressive disorder with anxiety (115 participants, sponsor BrainCells Inc.), was completed with a negative primary result and only a post-hoc subgroup signal; no follow-up trial was registered, leaving the depression-and-anxiety question open. - **Choline-transporter biology:** Continued basic research on the high-affinity choline transporter (CHT1) — including work showing its activation relieves stress-induced hyperalgesia ([Lin & Yu, 2018](https://pubmed.ncbi.nlm.nih.gov/30288092/)) — could clarify whether choline-uptake enhancement has therapeutic value beyond cognition, which would either strengthen or narrow the rationale for coluracetam. - **Glutamatergic and antidepressant context:** A review placing coluracetam among glutamate-modulating antidepressant candidates ([Dutta et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25467702/)) situates it within a broader, still-evolving search for novel mood treatments; future glutamate-cholinergic research could revive or further sideline interest. - **Need for controlled cognition studies:** The most decisive future research would be a placebo-controlled trial of coluracetam for cognition in healthy adults or in defined cholinergic-deficit populations; such a study could confirm the community's claims or, given the impaired-neuron-selective mechanism, weaken the case for use in healthy people. No such trial is currently registered. ## Conclusion Coluracetam is a synthetic racetam first developed in Japan as a memory-loss treatment and later tested, without success, for depression with anxiety. Its proposed action is to help nerve cells take up choline, the building block of a brain messenger tied to memory and attention. The most consistent evidence is from animal studies in which the brain's choline system was deliberately damaged: there, coluracetam restored choline uptake and improved learning. A striking detail is that this effect appears mostly in impaired, not healthy, brain tissue, which raises real doubt about whether it does much for an already-healthy person — and indeed there is no solid human evidence of cognitive benefit. The safety picture is shaped less by alarming findings than by missing information. Short-term use in its one human trial was well tolerated, and reported side effects — headache, nausea, tiredness, irritability — are mostly mild and tied to dose. But there is no long-term safety record, no approval anywhere, and the compound is sold as an unregulated research chemical, so product quality cannot be assumed. It is also worth keeping in mind that most of the favorable evidence came from the companies that developed and tested the compound, not from independent groups. Overall, the evidence base is thin and uncertain: a plausible mechanism and encouraging animal data sit alongside a failed human trial, a lack of long-term data, and unresolved questions about who, if anyone, would benefit. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**